Hamdi Osama A, Danan Deepa, Denner Amber, Bellinger Jeffrey R, Thornton Noah, Shonka David C, Garneau Jonathan C, Fedder Katherine, Jameson Mark J, Dowling Eric M
Department of Otolaryngology-Head and Neck Surgery University of Virginia Charlottesville Virginia USA.
Department of Otolaryngology-Head and Neck Surgery University of Florida Gainesville Florida USA.
Laryngoscope Investig Otolaryngol. 2024 Oct 18;9(5):e70021. doi: 10.1002/lio2.70021. eCollection 2024 Oct.
Recent literature studying the impact of blood transfusion on outcomes in patients with head and neck cancer (HNC) have shown that blood transfusions are associated with increased risk of death and higher wound infection rates. The purpose of this study was to implement a lower transfusion threshold while comparing outcomes of free flap patients following initiation of a new transfusion guideline.
A retrospective study of all patients at a tertiary care academic center who underwent free tissue transfer after HNC resection between July 17, 2007 and June 7, 2021. Transfusion criteria were adjusted in 2014; the hematocrit threshold to transfuse was incrementally reduced from 30% in 2007 to 21% in 2017. The main outcomes of interest were overall survival (OS) and recurrence free survival (RFS).
A total of 346 patients met the criteria for inclusion in the study. Groups 1 (less strict protocol - 30%) and 2 (stricter protocol - 21%) consisted of 171 and 175 patients, respectively. Fewer units of packed red cells were transfused per patient in group 2 (0.26 vs. 2.87 in group 1, < .001). Group 1 was associated with worse OS ( = .01; hazard ratio [HR] = 1.7) and RFS ( < .001; HR = 2.5). Comparing only patients with SCC between the two groups also demonstrated poorer OS ( = .01; HR = 1.8) and RFS ( = .006; HR = 2.1) in group 1.
In HNC patients undergoing free tissue transfer, stricter transfusion criteria with threshold hematocrit of 21% was associated with improved OS, RFS, and complication rates with no negative impact on free flap survival.
Level IV.
近期有关输血对头颈癌(HNC)患者预后影响的文献表明,输血与死亡风险增加及伤口感染率升高相关。本研究的目的是在比较新输血指南实施后游离皮瓣患者的预后时,采用较低的输血阈值。
对2007年7月17日至2021年6月7日期间在一家三级医疗学术中心接受HNC切除术后进行游离组织移植的所有患者进行回顾性研究。2014年调整了输血标准;输血的血细胞比容阈值从2007年的30%逐步降至2017年的21%。主要关注的结局是总生存期(OS)和无复发生存期(RFS)。
共有346例患者符合纳入本研究的标准。第1组(较宽松方案 - 30%)和第2组(较严格方案 - 21%)分别由171例和175例患者组成。第2组每位患者输注的浓缩红细胞单位较少(第1组为2.87,第2组为0.26,P <.001)。第1组的OS(P = 0.01;风险比[HR] = 1.7)和RFS(P <.001;HR = 2.5)较差。两组间仅比较鳞状细胞癌患者时,第1组的OS(P = 0.01;HR = 1.8)和RFS(P = 0.006;HR = 2.1)也较差。
在接受游离组织移植的HNC患者中,血细胞比容阈值为21%的更严格输血标准与OS、RFS改善及并发症发生率降低相关,且对游离皮瓣存活无负面影响。证据级别:四级。